<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4CB55502-EF06-4029-B368-F009E3EE8C01"><gtr:id>4CB55502-EF06-4029-B368-F009E3EE8C01</gtr:id><gtr:name>Ossianix</gtr:name><gtr:address><gtr:line1>3711 Market Street</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:department>Neuroscience Physiology and Pharmacology</gtr:department><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4CB55502-EF06-4029-B368-F009E3EE8C01"><gtr:id>4CB55502-EF06-4029-B368-F009E3EE8C01</gtr:id><gtr:name>Ossianix</gtr:name><gtr:address><gtr:line1>3711 Market Street</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/78132E4B-F641-45DF-A5A9-D1CF2558D7C4"><gtr:id>78132E4B-F641-45DF-A5A9-D1CF2558D7C4</gtr:id><gtr:firstName>Trevor Graeme</gtr:firstName><gtr:surname>Smart</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/0F1DDEF3-D842-45D2-A70A-793F992C0639"><gtr:id>0F1DDEF3-D842-45D2-A70A-793F992C0639</gtr:id><gtr:firstName>Damian</gtr:firstName><gtr:otherNames>Penderell</gtr:otherNames><gtr:surname>Bright</gtr:surname><gtr:roles><gtr:role><gtr:name>RESEARCHER</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/5EDDF8D3-8936-43C4-863F-DB188A8F3AC7"><gtr:id>5EDDF8D3-8936-43C4-863F-DB188A8F3AC7</gtr:id><gtr:firstName>Martin</gtr:firstName><gtr:surname>Mortensen</gtr:surname><gtr:roles><gtr:role><gtr:name>RESEARCHER</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/924B3090-0273-487D-BA18-20B4CE9C5EE0"><gtr:id>924B3090-0273-487D-BA18-20B4CE9C5EE0</gtr:id><gtr:firstName>Marc</gtr:firstName><gtr:otherNames>Christian</gtr:otherNames><gtr:surname>Gielen</gtr:surname><gtr:roles><gtr:role><gtr:name>RESEARCHER</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/4C521556-823A-457B-931F-424427AF13A0"><gtr:id>4C521556-823A-457B-931F-424427AF13A0</gtr:id><gtr:firstName>stephen</gtr:firstName><gtr:surname>Moss</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MR%2FK005537%2F1"><gtr:id>CDEEDAB4-1E3C-4AB4-8577-239C6AAD484F</gtr:id><gtr:title>Neurosteroids and GABA-A receptors and their roles in neuropsychiatric disorders</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MR/K005537/1</gtr:grantReference><gtr:abstractText>The brain receives and sorts information by individual nerve cells communicating with each other using a process known as chemical neurotransmission. This involves networks of cells becoming broadly excited or inhibited to control key aspects of mental function such as memory and the overall behaviour of individuals. The basis for this is the release of chemicals (neurotransmitters) from one nerve cell that binds to specific protein receptors on another, to cause excitation or inhibition. One major neurotransmitter in the brain is GABA. It is responsible for dampening nerve cell excitation by causing inhibition - it does this by interacting with a class of receptors known as GABA-A receptors (GABA-ARs). Most nerve cells in the brain will possess GABAARs underlining the pivotal role that they play in fundamental aspects of brain function including the following examples of - cognition, memory, sleep, sensation, control of muscle movement and response to stress. Indeed, so important are these receptors that their dysfunction is directly implicated in numerous and serious neurological and mental health disorders, such as anxiety and depression, epilepsy, schizophrenia, pain, substance addiction, autism, Down's and Fragile-X syndromes, to name only a few. As a consequence, GABAARs are widely recognised as molecular targets for therapeutic drug classes that include the benzodiazepines (BDZs) and general anaesthetics. 

Of equal significance, GABA-ARs are also subject to regulation by a number of endogenous agents in the brain. Prime amongst these are the neurosteroids, which are released from cells and can potentiate GABA-AR function at very low concentrations. Dysfunctional neurosteroid production is also implicated in neurological diseases, such as anxiety and depression, pain and catamenial epilepsy, and this is thought to involve altered GABA-AR function. It is therefore critical to understand how neurosteroids regulate GABA-ARs, what neural circuits are involved, how this contributes to disease, and how neurosteroids may be used as therapeutic agents. Our recent breakthrough in identifying the molecular basis for neurosteroid binding sites on GABA-ARs enables us to address these questions and determine precisely which types of GABA-ARs are involved in particular actions of the neurosteroids. 

Our aims are to use a combination of techniques, some involving genetic engineering, to determine how neurosteroids regulate selected GABA-ARs and to broaden our understanding of neuropsychiatric disease when neurosteroid regulation becomes dysfunctional. We will use the neurosteroid modulatory site on GABA-ARs to facilitate the development of novel therapeutics for the treatment of neurological disorders. Our aim is to improve understanding of mechanisms that may precipitate mental illness and to provide new approaches to its prevention and treatment.

Specifically, we have four goals - (i) to examine what actions of the neurosteroids are mediated by a specific isoform of the GABA-AR that is involved in mediating anxiety and pain; (ii) to understand how modification of GABA-ARs by naturally-occurring enzymes in the brain affects neurosteroid modulation; (iii) to probe these interactions with neurosteroids at another important GABA-AR that is involved in dampening excitation and is implicated in substance addiction; and (iv) to examine how we can develop new neurosteroid agents for therapeutic benefit.

The outcomes from our programme of work will have many implications. Chiefly, it will provide much needed information on the basis by which neurosteroids work in the brain, how they regulate GABA-ARs under physiological conditions and what happens during dysfunction to precipitate disease. By exploring the neurosteroid binding site, we now have for the first time, an opportunity to provide new impetus for the treatment of neurological diseases.</gtr:abstractText><gtr:technicalSummary>We will examine how neurosteroids exert their effects via specific GABA-AR isoforms and the consequences for neuropsychiatric disease when this becomes dysfunctional. Our aim is to better understand some of the mechanisms that precipitate mental illness and to provide new approaches for its prevention and treatment by exploiting our knowledge of the neurosteroid modulatory site on GABA-ARs. A combination of cellular, molecular and genetic techniques will examine the roles of neurosteroids using recombinant GABA-ARs in expression systems and native GABA-ARs in cell cultures or brain slices.

Whole-cell patch clamp recording methods will measure GABA synaptic and tonic inhibition and associated kinetic parameters. Biochemical (Western blots, phosphorylation) and immunocytochemical techniques (antibody labelling, phosphorylation-specific antibodies, Tirf microscopy) will measure changes to GABA-AR composition, and single particle tracking with quantum dots and the bungarotoxin binding site will monitor GABA-AR mobility. New transgenic animals will help to explore the interactions between GABA-AR phosphorylation and neurosteroid modulation with regard to synaptic and tonic inhibition. 

Behavioural techniques will examine how neurosteroids affect intact brain function and the consequences that follow when this becomes dysfunctional. We will use structure-function approaches to probe the neurosteroid binding site and transplant it into other receptors to gain valuable information on key structural determinants. We will design (collab. with UCL Chemistry and Industry) new neurosteroid molecules that could be therapeutically beneficial by targeting specific isoforms of the GABA-AR.

Our research programme will contribute to our understanding of brain function. It will help us to understand how neurological diseases can be precipitated by dysfunctional neurosteroid signalling, as well as providing new insight into novel therapeutic strategies for mental health.</gtr:technicalSummary><gtr:potentialImpactText>For Academic, Economic and Societal Impact, our proposed programme is likely to have broad-ranging effects on several groups. These include academics, and in the longer-term, healthcare professionals associated with mental health. We also expect the general/lay public who are directly or indirectly affected by poor mental health to benefit, as well as pharmaceutical companies concerned with drug development for mental health disorders. 

Academics will gain valuable insight into precisely how neurosteroids function in the brain as well as achieving a better understanding of their role in mental illness. We will engender Capacity Building Impact by training new generations of scientists to use innovative technologies and methods, as well as providing clinicians with potentially new therapeutic targets for treating mental illness. Our previous collaborative studies of inhibitory synaptic transmission provide direct evidence of translation relevant to inherited neurological disorders by providing molecular diagnostics and potential therapeutic remedies (Rees et al 2006, Nature Genet 38, 801-806). In the longer term, we predict our programme has the potential to lead to improved quality of life for patients, family members, carers and indeed medical staff.

Our research programme is designed to enable a greater understanding of brain function by providing new knowledge regarding GABA-mediated synaptic and tonic inhibition and how modulation by neurosteroids can cause and affect neuropsychiatric disease. These findings are expected to be at least partly-translated across scientific disciplines during the time-course of the programme. We will ensure promulgation of our findings by presentations at major international conferences, by engaging in invited lectures in the UK and abroad to scientific and lay audiences, by publishing in internationally-recognised high quality scientific journals, and by engaging with national/international press, television and radio as appropriate. 

If patentable results arise from our research programme, and this is potentially likely, UCL has excellent support structures to enable us to proceed and exploit our discoveries. Indeed, with regard to the discovery of neurosteroid binding sites, a patent has been issued with a view to encouraging interactions with the pharmaceutical industry.

In the longer term, understanding how neurosteroids and GABA receptors contribute to neurological disease could improve our identification of new components involved in disease pathology. This is particularly relevant for an ageing population where the prevalence of neural diseases is projected to increase and is in urgent need of new therapeutic initiatives.</gtr:potentialImpactText><gtr:fund><gtr:end>2019-06-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2013-07-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1369785</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Chemistry</gtr:department><gtr:description>Light-modulated nanotweezers for activating ligand-gated ion channels</gtr:description><gtr:id>BCAE77CF-484A-4775-8A3E-9242CE65C226</gtr:id><gtr:impact>Mortensen et al 2014 Photoantagonism of the GABA-A receptor Nature communications DOI: 10.1038/ncomms5454

Mortensen &amp;amp; Smart 2016 Neuronal inhibition in the spotlight. Neuron 88, 845-847</gtr:impact><gtr:outcomeId>56d94d8c2a00a8.65627174-1</gtr:outcomeId><gtr:partnerContribution>Synthesis of the new chemical entity based on an azobenezene light sensitive module</gtr:partnerContribution><gtr:piContribution>Designed a new chemical entity that when bound to two cysteine residues at a critical part of a receptor protein, is capable of activating the receptor by changing the conformation of the chemical using light.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Neurology</gtr:department><gtr:description>Down's syndrome and cognition</gtr:description><gtr:id>10573132-A2F7-43DE-B755-9AD152A7CDE2</gtr:id><gtr:impact>Analysing the strategy of treating Down's syndrome patients with GABA antagonists</gtr:impact><gtr:outcomeId>TYTwhwZqTkq-1</gtr:outcomeId><gtr:partnerContribution>Access to chemical leads and clinical trials design</gtr:partnerContribution><gtr:piContribution>Advising on the use of GABA atnagonists to improve cognition</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Chemistry</gtr:department><gtr:description>Photo-chemical labelling of the GABA receptor</gtr:description><gtr:id>ECB4C534-38DC-4DA1-B986-2B6BE1D337F8</gtr:id><gtr:impact>Paper submitted</gtr:impact><gtr:outcomeId>W96MEv7bD1p-1</gtr:outcomeId><gtr:partnerContribution>Design of novel photochemical ligands</gtr:partnerContribution><gtr:piContribution>Collaboration with UCL Chmiestry in the design of photo-active ligands for the GABA-A receptor</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Ossianix</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Variable new antigen receptors for delivering drugs</gtr:description><gtr:id>B0DE1C82-ED28-47C6-BCC3-6AA29FC9F7C5</gtr:id><gtr:impact>None so far</gtr:impact><gtr:outcomeId>58be74df143c52.88359984-1</gtr:outcomeId><gtr:partnerContribution>Ossianix will help us to immunise sharks for producing variable new antigen receptors (VNARS) and in the process of selecting those VNARS that target our specified GABA-A receptors.


UCL Chemistry - colleagues here are assisting us in linking drug molecules to the VNARs.</gtr:partnerContribution><gtr:piContribution>We have provided the IP, the idea for targeting drugs to specific GABAA receptors using single strand antibodies.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Max Delbruck Centrum fur Molekulare Medizin - Lecture</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>7121158C-F6F5-474E-83BB-C0E8C98EABAE</gtr:id><gtr:impact>Lecture on allosteric and genetic modulation of GABA-A receptors</gtr:impact><gtr:outcomeId>58be8873b2b034.92894176</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Allo- and genetic modulation of GABAA receptors</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>E2A97672-E158-482D-8C40-0CF87251912C</gtr:id><gtr:impact>National University of Singapore. Plenary lecture. Allosteric and Genetic modulation of GABAA receptors.</gtr:impact><gtr:outcomeId>56d98289962bd7.10461170</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Allosteric and Genetic modulation of GABAA receptors</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>FA522CF9-21C2-4E8A-B21D-D278E59AF745</gtr:id><gtr:impact>Kings College London. Wolfson Centre for Age-Related Diseases.</gtr:impact><gtr:outcomeId>56d982cf014205.92354775</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Molecular mechanisms of glycine receptor function</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>861799E7-42A0-434D-81F3-59EA81BBD339</gtr:id><gtr:impact>British Pharmacological Society Winter meeting, London. Symposium on Glycinergic transmission: Physiological, developmental and pathological implications.</gtr:impact><gtr:outcomeId>56d9810e2e21b4.43229340</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Modulating GABA inhibition</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>1EDC801E-2E52-4B28-840D-EA78DB5DE3A0</gtr:id><gtr:impact>Research seminar to Center for Brain Research, Medical University Vienna, Austria</gtr:impact><gtr:outcomeId>56d97be1753a99.82345744</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Allo- and Orthosteric modulation of GABA receptors</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>70E6E9D7-A165-4C58-A1BE-AEBDF0DF58BC</gtr:id><gtr:impact>Seminar to Univ. Copenhagen. Faculty of Health and Medical Sciences</gtr:impact><gtr:outcomeId>56d97c4dab5871.52975244</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>National University of Singapore</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>8AC9F63B-BD7C-441E-94EB-7BA6773D7A63</gtr:id><gtr:impact>Lecture - Allosteric and Genetic modulation of GABAA receptors.</gtr:impact><gtr:outcomeId>58be89de9a21f8.81772121</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Bordeaux Neuroscience Federation</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>F1F092B5-01F8-458F-B3B8-33EE0B1562AC</gtr:id><gtr:impact>Lecture on plasticity of inhibitory synaptic neurotransmission.</gtr:impact><gtr:outcomeId>58be88c4e34985.53553878</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MAC 2015 Conference, Bonn</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>E92FA88B-E61D-4A2B-B43C-63B6FB96E749</gtr:id><gtr:impact>Lecture - Extrasynaptic GABAA receptors and general anaesthesia. Which receptors produce tonic neuronal chloride currents?</gtr:impact><gtr:outcomeId>58be894541d9d8.65549520</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Humphrey Rang BPS 80th Symposium</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>DADA534A-76DB-4D7F-9605-7DC7A5C3DD1D</gtr:id><gtr:impact>Lecture - Humphrey 50 yrs of drug use - receptors then and now.</gtr:impact><gtr:outcomeId>58be8a852bedb1.57634491</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>24th Neuropharmacology conference on GABAergic signalling in health and disease</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>4AC59FE3-F4E8-4E85-A058-CCC671140D78</gtr:id><gtr:impact>Major international conference on GABA signalling in the brain. Report to a scientific international conference at Washington DC.</gtr:impact><gtr:outcomeId>58be8646e39cc6.76238959</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>A mechanism for desensitisation</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>2D844F52-4E68-42FE-A766-297E5826CF4E</gtr:id><gtr:impact>MAC 2015 Conference, Bonn. Role of GABAA receptors in anaesthetic action.</gtr:impact><gtr:outcomeId>56d9815f611e31.61884190</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MAC 2015 Conference</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>D224404A-8C54-478B-9DA0-76C0E3D22052</gtr:id><gtr:impact>Role of GABAA receptors in anaesthetic action: A mechanism for GABA receptor desensitization</gtr:impact><gtr:outcomeId>58be8905755506.51839544</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>GABA receptors underlying tonic inhibition</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>DCDCE71A-060E-4EB9-9BC5-80B35E1759E6</gtr:id><gtr:impact>MAC 2015 Conference, Bonn. Extrasynaptic GABAA receptors and general anaesthesia.</gtr:impact><gtr:outcomeId>56d981d79494a3.48912350</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Kings College London. Wolfson Centre for Age-Related Diseases.</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>8C420C59-77C9-4F76-A070-8038FB37E8A6</gtr:id><gtr:impact>Lecture - Allosteric and Genetic modulation of GABAA receptors</gtr:impact><gtr:outcomeId>58be8a3bc24ad7.18467621</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Probing regulatory mechanisms for GABA-A receptors</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>42523636-4F48-42CA-8652-B4A8600E8563</gtr:id><gtr:impact>24th. Neuropharmacology conference on GABAergic Signaling in Health and Disease, Washington DC.</gtr:impact><gtr:outcomeId>56d97eb899d399.23182412</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>British Pharmacological Society Winter meeting</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>44BA2266-AEA0-4651-9F97-75D433904FBC</gtr:id><gtr:impact>Symposium on glycinergic transmission: physiological, developmental and pathological implications</gtr:impact><gtr:outcomeId>58be8753610c24.61795222</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other audiences</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Allosteric and genetic modulation of GABA receptors</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>0DC096C2-C601-4401-93E3-A9E113AE3509</gtr:id><gtr:impact>Foster Club Cambridge. Dept of Physiology seminar</gtr:impact><gtr:outcomeId>56d97e500dd255.24563978</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>European Congress of Pharmacology</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>D21325BA-944E-4B50-9EF6-A7F772871200</gtr:id><gtr:impact>Research seminar to the European Congress of Pharmacology</gtr:impact><gtr:outcomeId>56d979f4eb7847.70141610</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Sunburst Brain Camp National University of Singapore.</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>F07D78C5-DD9B-429F-892D-D9FE1E31DB63</gtr:id><gtr:impact>Lay lecture - Feeling inhibited - is it good for our brains?</gtr:impact><gtr:outcomeId>58be89a0538195.05174828</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Psychoactive drugs</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>8A91293A-4D45-449A-947C-BBA0D10BC213</gtr:id><gtr:outcomeId>56d983ae9e12f0.17633965</gtr:outcomeId><gtr:type>Implementation circular/rapid advice/letter to e.g. Ministry of Health</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:description>MRC funded work, currently trying to devise a method for enabling this drug to pass through the blood brain barrier</gtr:description><gtr:id>56283B6A-6F91-4422-ACE1-8AF2364964D5</gtr:id><gtr:impact>Development process clearly indicates this is a potentially viable route for the treatment of absence epilepsy.</gtr:impact><gtr:outcomeId>pidyzGoM8rm</gtr:outcomeId><gtr:stage>Refinement.  Non-clinical</gtr:stage><gtr:status>Actively seeking support</gtr:status><gtr:title>Partial agonist for absence epilepsy</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2015</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>Photoactive compounds capable of irreversibly modifying the function of GABA receptors</gtr:description><gtr:id>0CF42C92-E53F-4A3A-9D0A-5D4477E4401C</gtr:id><gtr:impact>Potential appication in epilepsy and cognition. Compounds allow tracking of natvie GABA receptors in real time.</gtr:impact><gtr:outcomeId>h1HoA4mSxTs</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Photoactive chemical probes</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2015</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>New GABA receptor antagonists made incorporating an azobenzene moiety to enable light control of activity</gtr:description><gtr:id>03E43314-200A-46A1-A894-AF45CCF132C9</gtr:id><gtr:impact>We are able to inhibit selected GABA receptors using light alone in conjunction with the new chemical compounds</gtr:impact><gtr:outcomeId>56d9747fd31989.68979111</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Azobenzene GABA receptor ligands</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>51126CC3-FC30-47EC-9D66-42901C92D1BF</gtr:id><gtr:title>Photo-antagonism of the GABAA receptor.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/30373c619109bc39028647979ba3b159"><gtr:id>30373c619109bc39028647979ba3b159</gtr:id><gtr:otherNames>Mortensen M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>5460e9954bfde9.46730703</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C9F3B5F7-0CAC-4126-B0BC-B60F0F53B0FE</gtr:id><gtr:title>Effects of Gabra2 Point Mutations on Alcohol Intake: Increased Binge-Like and Blunted Chronic Drinking by Mice.</gtr:title><gtr:parentPublicationTitle>Alcoholism, clinical and experimental research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1d017fac81052432a833b4574ec4c2b9"><gtr:id>1d017fac81052432a833b4574ec4c2b9</gtr:id><gtr:otherNames>Newman EL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0145-6008</gtr:issn><gtr:outcomeId>5aa0f07617a871.61332399</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A5C15556-E60D-4741-98CE-CDE878F33C1B</gtr:id><gtr:title>Mutations in the Gabrb1 gene promote alcohol consumption through increased tonic inhibition.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/24c89a46bc4fc9d556fe9b4dc2be9826"><gtr:id>24c89a46bc4fc9d556fe9b4dc2be9826</gtr:id><gtr:otherNames>Anstee QM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>5460e994be33b8.58440844</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E67138D9-2264-43E6-9682-973CE047FE99</gtr:id><gtr:title>Inhibitory neurosteroids and the GABAA receptor.</gtr:title><gtr:parentPublicationTitle>Advances in pharmacology (San Diego, Calif.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/beb2ab57cd293c4338a615a7a5f17cda"><gtr:id>beb2ab57cd293c4338a615a7a5f17cda</gtr:id><gtr:otherNames>Seljeset S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1054-3589</gtr:issn><gtr:outcomeId>58be7f9e6f5b01.52092813</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A465624A-44C5-4890-ADF8-1FB7106C2606</gtr:id><gtr:title>Tracking cell surface mobility of GPCRs using a-bungarotoxin-linked fluorophores.</gtr:title><gtr:parentPublicationTitle>Methods in enzymology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b73c51219133dc391ce8829da2883a79"><gtr:id>b73c51219133dc391ce8829da2883a79</gtr:id><gtr:otherNames>Hannan S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0076-6879</gtr:issn><gtr:outcomeId>5460e8cf81d1a6.98524286</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BF82ACAE-909C-4ABC-AE6A-6A9A54350BB1</gtr:id><gtr:title>Phospho-dependent Accumulation of GABABRs at Presynaptic Terminals after NMDAR Activation.</gtr:title><gtr:parentPublicationTitle>Cell reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b73c51219133dc391ce8829da2883a79"><gtr:id>b73c51219133dc391ce8829da2883a79</gtr:id><gtr:otherNames>Hannan S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:outcomeId>58be7f60040ab0.68187566</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>929D841A-68A8-421A-A4DA-ADF396DD0748</gtr:id><gtr:title>Methods for recording and measuring tonic GABAA receptor-mediated inhibition.</gtr:title><gtr:parentPublicationTitle>Frontiers in neural circuits</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/82c54f6664014fc5b56ca55b75e7d3ec"><gtr:id>82c54f6664014fc5b56ca55b75e7d3ec</gtr:id><gtr:otherNames>Bright DP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1662-5110</gtr:issn><gtr:outcomeId>5460e994e9e172.84829951</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A46D9F19-A882-45D9-8911-B55E488A143A</gtr:id><gtr:title>Epilepsy and intellectual disability linked protein Shrm4 interaction with GABARs shapes inhibitory neurotransmission.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2f9359c1a3a1712c52b07c301cdf616d"><gtr:id>2f9359c1a3a1712c52b07c301cdf616d</gtr:id><gtr:otherNames>Zapata J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>5aa0f165a6db68.48842773</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6A0B4BBD-9715-4CDA-9E0E-67C2C831590F</gtr:id><gtr:title>Probing GABAreceptors with inhibitory neurosteroids.</gtr:title><gtr:parentPublicationTitle>Neuropharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/beb2ab57cd293c4338a615a7a5f17cda"><gtr:id>beb2ab57cd293c4338a615a7a5f17cda</gtr:id><gtr:otherNames>Seljeset S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0028-3908</gtr:issn><gtr:outcomeId>5aa0f0e7636601.98570554</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5FE96965-9B0F-4BF5-91FD-DEE01CB3FAA9</gtr:id><gtr:title>The Concise Guide to PHARMACOLOGY 2013/14: overview.</gtr:title><gtr:parentPublicationTitle>British journal of pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/22eb2c18ba534f4f36ee595a2e355c9a"><gtr:id>22eb2c18ba534f4f36ee595a2e355c9a</gtr:id><gtr:otherNames>Alexander SP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0007-1188</gtr:issn><gtr:outcomeId>5460e995243b30.11062275</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C22BA7ED-1E6E-4F11-8C65-0EC89D23B2AD</gtr:id><gtr:title>The desensitization gate of inhibitory Cys-loop receptors.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/31eb5dcad5e138661d2ce355ea97b512"><gtr:id>31eb5dcad5e138661d2ce355ea97b512</gtr:id><gtr:otherNames>Gielen M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>5675e2c496f02</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>708FA5F5-1E04-412B-A115-C43BA456448A</gtr:id><gtr:title>Brief report: isogenic induced pluripotent stem cell lines from an adult with mosaic down syndrome model accelerated neuronal ageing and neurodegeneration.</gtr:title><gtr:parentPublicationTitle>Stem cells (Dayton, Ohio)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e39ad0918732f409ce3b1988893923c0"><gtr:id>e39ad0918732f409ce3b1988893923c0</gtr:id><gtr:otherNames>Murray A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1066-5099</gtr:issn><gtr:outcomeId>58be7de20fe2e7.65665447</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C78E218A-6119-4DC7-8255-057AC3899FB4</gtr:id><gtr:title>Modulation of neurosteroid potentiation by protein kinases at synaptic- and extrasynaptic-type GABAA receptors.</gtr:title><gtr:parentPublicationTitle>Neuropharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/430a0a05d0840b873b0275c39d23257b"><gtr:id>430a0a05d0840b873b0275c39d23257b</gtr:id><gtr:otherNames>Adams JM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0028-3908</gtr:issn><gtr:outcomeId>5460e995726d92.29265473</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>16FF5A72-C45A-48AB-B762-26E6667F3ED5</gtr:id><gtr:title>Snake neurotoxin a-bungarotoxin is an antagonist at native GABA(A) receptors.</gtr:title><gtr:parentPublicationTitle>Neuropharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b73c51219133dc391ce8829da2883a79"><gtr:id>b73c51219133dc391ce8829da2883a79</gtr:id><gtr:otherNames>Hannan S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0028-3908</gtr:issn><gtr:outcomeId>58be7da6bb2729.14927047</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ABB808A5-6196-4175-893E-A58C9D787500</gtr:id><gtr:title>Interneuron- and GABA(A) receptor-specific inhibitory synaptic plasticity in cerebellar Purkinje cells.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/562fed8607270200b21f5bfbcffc69d9"><gtr:id>562fed8607270200b21f5bfbcffc69d9</gtr:id><gtr:otherNames>He Q</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>58be7eaa863bc1.47028765</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>712D3CA2-8205-4F4E-8461-E4C0D42ED3B4</gtr:id><gtr:title>Neuronal Inhibition under the Spotlight.</gtr:title><gtr:parentPublicationTitle>Neuron</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/30373c619109bc39028647979ba3b159"><gtr:id>30373c619109bc39028647979ba3b159</gtr:id><gtr:otherNames>Mortensen M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0896-6273</gtr:issn><gtr:outcomeId>58be7ed73de728.74409434</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E954C684-B8E2-474A-B469-328B0F3C66B0</gtr:id><gtr:title>Tyrosine phosphorylation of GABAA receptor ?2-subunit regulates tonic and phasic inhibition in the thalamus.</gtr:title><gtr:parentPublicationTitle>The Journal of neuroscience : the official journal of the Society for Neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/66442a35b6f19652f9d706c45ab88e52"><gtr:id>66442a35b6f19652f9d706c45ab88e52</gtr:id><gtr:otherNames>Nani F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0270-6474</gtr:issn><gtr:outcomeId>5460e8cfa6a740.46317619</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9FA0E74D-A707-4753-8699-1278BF7FD53F</gtr:id><gtr:title>Azogabazine; a photochromic antagonist of the GABAA receptor.</gtr:title><gtr:parentPublicationTitle>Organic &amp; biomolecular chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a49d56b1b6092a903f27b93ea91dc2fc"><gtr:id>a49d56b1b6092a903f27b93ea91dc2fc</gtr:id><gtr:otherNames>Huckvale R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1477-0520</gtr:issn><gtr:outcomeId>5aa0ef5485f574.11492344</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8A0B77E9-DADC-47C8-BFD9-3AC08D86AC3E</gtr:id><gtr:title>Stoichiometry of d subunit containing GABA(A) receptors.</gtr:title><gtr:parentPublicationTitle>British journal of pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6aec540d396589c835fdbd03ad39ca12"><gtr:id>6aec540d396589c835fdbd03ad39ca12</gtr:id><gtr:otherNames>Patel B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0007-1188</gtr:issn><gtr:outcomeId>5460e994931846.42164673</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4440ECB7-B1AE-47A4-AF5F-D06190F75B3D</gtr:id><gtr:title>Crystal structures of a GABA-receptor chimera reveal new endogenous neurosteroid-binding sites.</gtr:title><gtr:parentPublicationTitle>Nature structural &amp; molecular biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ba26b6936aa8398d67e4315d420dafa2"><gtr:id>ba26b6936aa8398d67e4315d420dafa2</gtr:id><gtr:otherNames>Laverty D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1545-9985</gtr:issn><gtr:outcomeId>5aa0f01c3a0513.53832683</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>242AA973-DC55-4C94-8E71-E44BC4000844</gtr:id><gtr:title>Radixin regulates synaptic GABAA receptor density and is essential for reversal learning and short-term memory.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e39e97f708a86975fe0466cc9944674d"><gtr:id>e39e97f708a86975fe0466cc9944674d</gtr:id><gtr:otherNames>Hausrat TJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>58be7e6bc9a962.09607113</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F66E9FDC-145E-4AF5-AA73-E0BADCCE6A95</gtr:id><gtr:title>Disrupting the clustering of GABAA receptor a2 subunits in the frontal cortex leads to reduced ?-power and cognitive deficits.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0e50ac784f502f34a79646fea6efb917"><gtr:id>0e50ac784f502f34a79646fea6efb917</gtr:id><gtr:otherNames>Hines RM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>5460e8cfe791b4.17183867</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5E864208-3275-4EB5-AF9F-6C8C7967F50C</gtr:id><gtr:title>Murine startle mutant Nmf11 affects the structural stability of the glycine receptor and increases deactivation.</gtr:title><gtr:parentPublicationTitle>The Journal of physiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ed0fd074168237c1eedafa78e4dc1a0c"><gtr:id>ed0fd074168237c1eedafa78e4dc1a0c</gtr:id><gtr:otherNames>Wilkins ME</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0022-3751</gtr:issn><gtr:outcomeId>58be7f307fa963.20422000</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>94167585-9E62-420C-A13E-074377EEAB2B</gtr:id><gtr:title>Protein kinase C regulates tonic GABA(A) receptor-mediated inhibition in the hippocampus and thalamus.</gtr:title><gtr:parentPublicationTitle>The European journal of neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/82c54f6664014fc5b56ca55b75e7d3ec"><gtr:id>82c54f6664014fc5b56ca55b75e7d3ec</gtr:id><gtr:otherNames>Bright DP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0953-816X</gtr:issn><gtr:outcomeId>5460e8d02524d2.81055074</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4445E1AE-3802-468E-B8BF-231FD857BBCA</gtr:id><gtr:title>Context-Dependent Modulation of GABAAR-Mediated Tonic Currents.</gtr:title><gtr:parentPublicationTitle>The Journal of neuroscience : the official journal of the Society for Neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6aec540d396589c835fdbd03ad39ca12"><gtr:id>6aec540d396589c835fdbd03ad39ca12</gtr:id><gtr:otherNames>Patel B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0270-6474</gtr:issn><gtr:outcomeId>58be7eff677a78.41063780</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D114199D-AF77-4004-B119-46B1BE98E383</gtr:id><gtr:title>Pharmacological characterisation of murine a4?1d GABAA receptors expressed in Xenopus oocytes.</gtr:title><gtr:parentPublicationTitle>BMC neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7d4f2af0a0dac508e2c72bcf5cbc9312"><gtr:id>7d4f2af0a0dac508e2c72bcf5cbc9312</gtr:id><gtr:otherNames>Villumsen IS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1471-2202</gtr:issn><gtr:outcomeId>58be7e2ac73712.59882915</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/K005537/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>3C193D18-12BD-4B15-8347-037BA623E0FF</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Mental Health</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>